Evaluation of the Effectiveness of Pneumococcal Conjugate Vaccines in Children
DOI:
https://doi.org/10.12775/JEHS.2026.87.67624Keywords
PCV, children, vaccine, streptococcus pneumoniae, invasive pneumococcal diseaseAbstract
Diseases caused by Streptococcus pneumoniae are one of the most common infectious causes of death worldwide, making them a major global burden. For this reason, pneumococcal conjugate vaccines (PCVs) are one of the key achievements in preventive medicine. PCVs are not only among the most widely used vaccines in the world but also have high clinical efficacy in preventing pneumococcal diseases, including invasive pneumococcal disease, meningitis, bacteremia, pneumonia, otitis media, and upper respiratory tract infections. In addition, PCVs contribute to herd immunity and reduce respiratory tract colonization with streptococci, particularly in newborns and infants, especially during the pre-vaccination period.
Due to their very good safety profile, including a low risk of serious adverse reactions and high immunogenicity, PCVs are an important part of international and national vaccination programs. Nevertheless, their availability remains limited in low- and middle-income countries.
The high replaceability and persistence of some serotypes, along with multi-drug resistance, keep Streptococcus pneumoniae infections as a major epidemiological challenge. This underscores the importance of monitoring variants and updating vaccination schedules. Modern PCVs now include more serotypes to combat these diseases, guiding future clinical research.
References
1. Mohanty S, Done N, Liu Q, Song Y, Wang T, Gaburo K, et al. Incidence of pneumococcal disease in children ≤48 months old in the United States: 1998-2019. Vaccine. 2024 Apr 19;42(11):2758–69.
2. Greenslade L. Antimicrobial resistance and pneumonia [Internet]. Every Breath Counts. 2022 [cited 2025 Dec 8]. Available from: https://stoppneumonia.org/statement-world-amr-awareness-week-2024/
3. Lucero MG, Dulalia VE, Nillos LT, Williams G, Parreño RAN, Nohynek H, et al. Pneumococcal conjugate vaccines for preventing vaccine-type invasive pneumococcal disease and X-ray defined pneumonia in children less than two years of age. Cochrane Database Syst Rev. 2009 Oct 7;2009(4):CD004977.
4. Tricarico S, McNeil HC, Cleary DW, Head MG, Lim V, Yap IKS, et al. Pneumococcal conjugate vaccine implementation in middle-income countries. Pneumonia Nathan Qld. 2017;9:6.
5. Reyburn R, Tsatsaronis A, von Mollendorf C, Mulholland K, Russell FM, ARI Review group. Systematic review on the impact of the pneumococcal conjugate vaccine ten valent (PCV10) or thirteen valent (PCV13) on all-cause, radiologically confirmed and severe pneumonia hospitalisation rates and pneumonia mortality in children 0-9 years old. J Glob Health. 2023 Feb 3;13:05002.
6. Torres A, Bonanni P, Hryniewicz W, Moutschen M, Reinert RR, Welte T. Pneumococcal vaccination: what have we learnt so far and what can we expect in the future? Eur J Clin Microbiol Infect Dis. 2015;34(1):19–31.
7. Xie Z, Li J, Wang X, Huang L, Gou J, Zhang W, et al. The Safety and Immunogenicity of a 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (CRM197/TT) in Infants: A Double-Blind, Randomized, Phase III Trial. Vaccines. 2024 Dec 16;12(12):1417.
8. Weinberger DM, Malley R, Lipsitch M. Serotype replacement in disease after pneumococcal vaccination. Lancet Lond Engl. 2011 Dec 3;378(9807):1962–73.
9. Choi EH, Kim KH, Kim YJ, Kim JH, Park SE, Lee HJ, et al. Recommendation for use of the newly introduced pneumococcal protein conjugate vaccines in Korea. Korean J Pediatr. 2011 Apr;54(4):146–51.
10. Wagner G, Gartlehner G, Thaler K, Ledinger D, Feyertag J, Klerings I, et al. Immunogenicity and safety of the 15-valent pneumococcal conjugate vaccine, a systematic review and meta-analysis. Npj Vaccines. 2024 Dec 30;9(1):257.
11. Rozenbaum MH, Huang L, Perdrizet J, Cane A, Arguedas A, Hayford K, et al. Cost-effectiveness of 20-valent pneumococcal conjugate vaccine in US infants. Vaccine. 2024 Jan 25;42(3):573–82.
12. Chen CH, Chen CL, Su LH, Chen CJ, Tsai MH, Chiu CH. The microbiological characteristics and diagnosis of Streptococcus pneumoniae infection in the conjugate vaccine era. Hum Vaccines Immunother. 2025 Dec;21(1):2497611.
13. Senders S, Klein NP, Tamimi N, Thompson A, Baugher G, Trammel J, et al. A Phase Three Study of the Safety and Immunogenicity of a Four-dose Series of 20-Valent Pneumococcal Conjugate Vaccine in Healthy Infants. Pediatr Infect Dis J. 2024 June 1;43(6):596–603.
14. Huang L, Li X, Eugenia N, Leung J, Hung STA, Cheong EZB, et al. Burden of Pneumococcal Disease in Young Children Due to Serotypes Contained in Different Pneumococcal Conjugate Vaccines in Eight Asian Countries and Territories. Vaccines. 2024 Oct 19;12(10):1197.
15. Versluys KA, Eurich DT, Marrie TJ, Forgie S, Tyrrell GJ. Invasive pneumococcal disease and long-term outcomes in children: A 20-year population cohort study. Lancet Reg Health Am. 2022 Oct;14:100341.
16. Bennett JC, Deloria Knoll M, Kagucia EW, Garcia Quesada M, Zeger SL, Hetrich MK, et al. Global impact of ten-valent and 13-valent pneumococcal conjugate vaccines on invasive pneumococcal disease in all ages (the PSERENADE project): a global surveillance analysis. Lancet Infect Dis. 2025 Apr;25(4):457–70.
17. Mrkvan T, Pelton SI, Ruiz-Guiñazú J, Palmu AA, Borys D. Effectiveness and impact of the 10-valent pneumococcal conjugate vaccine, PHiD-CV: review of clinical trials and post-marketing experience. Expert Rev Vaccines. 2018 Sept;17(9):797–818.
18. Główny Inspektorat Sanitarny [Internet]. [cited 2025 Dec 12]. Program Szczepień Ochronnych na 2026 rok - Główny Inspektorat Sanitarny - Portal Gov.pl. Available from: https://www.gov.pl/web/gis/program-szczepien-ochronnych-na-2026-rok
19. Malchrzak W, Babicki M, Mastalerz-Migas A. Vaccination against Streptococcus pneumoniae in Children Born between 2015 and 2018 in Poland-How Has the Introduction of Free Compulsory Pneumococcal Vaccination Affected Its Uptake? Vaccines. 2023 Oct 28;11(11):1654.
20. WHO position paper: Pneumococcal conjugate vaccines in infants and children aged <5 years – September 2025 [Internet]. [cited 2025 Dec 12]. Available from: https://www.who.int/publications/i/item/who-wer10039-411-437
21. Powiatowa Stacja Sanitarno-Epidemiologiczna w Krakowie [Internet]. [cited 2025 Dec 12]. Rozporządzanie Ministra Zdrowia z dnia 27 września 2023 r. w sprawie obowiązkowych szczepień ochronnych - Powiatowa Stacja Sanitarno-Epidemiologiczna w Krakowie - Portal Gov.pl. Available from: https://www.gov.pl/web/psse-krakow/rozporzadzanie-ministra-zdrowia-z-dnia-27-wrzesnia-2023-r-w-sprawie-obowiazkowych-szczepien-ochronnych
22. Licciardi PV, Russell FM, Balloch A, Burton RL, Nahm MH, Gilbert G, et al. Impaired immune function following pneumococcal vaccination in infants with prior carriage. Vaccine. 2014 Apr 25;32(20):2321–7.
23. Shono A, Hoshi SL, Kondo M. Cost-effectiveness analyses of 20-valent pneumococcal conjugate vaccine in children and adults: A narrative review. Hum Vaccines Immunother. 2025 Dec;21(1):2525619.
24. Praktyczne aspekty realizacji szczepień przeciwko pneumokokom u dzieci [Internet]. [cited 2025 Dec 12]. Available from: http://www.mp.pl/social/article/379853
25. Flem E, Mouawad C, Palmu AA, Platt H, Johnson KD, McIntosh ED, et al. Indirect protection in adults ≥18 years of age from pediatric pneumococcal vaccination: a review. Expert Rev Vaccines. 2024;23(1):997–1010.
26. Senders S, Klein NP, Lamberth E, Thompson A, Drozd J, Trammel J, et al. Safety and Immunogenicity of a 20-valent Pneumococcal Conjugate Vaccine in Healthy Infants in the United States. Pediatr Infect Dis J. 2021 Oct 1;40(10):944–51.
27. Ekström N, Ahman H, Palmu A, Grönholm S, Kilpi T, Käyhty H, et al. Concentration and high avidity of pneumococcal antibodies persist at least 4 years after immunization with pneumococcal conjugate vaccine in infancy. Clin Vaccine Immunol CVI. 2013 July;20(7):1034–40.
28. Scott JAG, Ojal J, Ashton L, Muhoro A, Burbidge P, Goldblatt D. Pneumococcal conjugate vaccine given shortly after birth stimulates effective antibody concentrations and primes immunological memory for sustained infant protection. Clin Infect Dis Off Publ Infect Dis Soc Am. 2011 Oct;53(7):663–70.
29. Temple B, Tran HP, Dai VTT, Smith-Vaughan H, Balloch A, Beissbarth J, et al. Efficacy against pneumococcal carriage and the immunogenicity of reduced-dose (0 + 1 and 1 + 1) PCV10 and PCV13 schedules in Ho Chi Minh City, Viet Nam: a parallel, single-blind, randomised controlled trial. Lancet Infect Dis. 2023 Aug 1;23(8):933–44.
30. Clutterbuck EA, Oh S, Hamaluba M, Westcar S, Beverley PCL, Pollard AJ. Serotype-specific and age-dependent generation of pneumococcal polysaccharide-specific memory B-cell and antibody responses to immunization with a pneumococcal conjugate vaccine. Clin Vaccine Immunol CVI. 2008 Feb;15(2):182–93.
31. Tin Tin Htar M, Stuurman AL, Ferreira G, Alicino C, Bollaerts K, Paganino C, et al. Effectiveness of pneumococcal vaccines in preventing pneumonia in adults, a systematic review and meta-analyses of observational studies. PloS One. 2017;12(5):e0177985.
32. Pilishvili T, Gierke R, Farley MM, Schaffner W, Thomas A, Reingold A, et al. 1470. Epidemiology of Invasive Pneumococcal Disease (IPD) Following 18 years of Pneumococcal Conjugate Vaccine (PCV) Use in the United States. Open Forum Infect Dis. 2020 Dec 31;7(Suppl 1):S736–7.
33. Kielbik K, Pietras A, Jablonska J, Bakiera A, Borek A, Niedzielska G, et al. Impact of Pneumococcal Vaccination on Nasopharyngeal Carriage of Streptococcus pneumoniae and Microbiota Profiles in Preschool Children in South East Poland. Vaccines. 2022 May 17;10(5):791.
34. Ewald H, Briel M, Vuichard D, Kreutle V, Zhydkov A, Gloy V. The Clinical Effectiveness of Pneumococcal Conjugate Vaccines: A Systematic Review and Meta-analysis of Randomized Controlled Trials. Dtsch Arzteblatt Int. 2016 Mar 4;113(9):139–46.
35. Wannarong T, Ekpatanaparnich P, Boonyasiri A, Supapueng O, Vathanophas V, Tanphaichitr A, et al. Efficacy of Pneumococcal Vaccine on Otitis Media: A Systematic Review and Meta-Analysis. Otolaryngol--Head Neck Surg Off J Am Acad Otolaryngol-Head Neck Surg. 2023 Oct;169(4):765–79.
36. Lindstrand A, Bennet R, Galanis I, Blennow M, Ask LS, Dennison SH, et al. Sinusitis and pneumonia hospitalization after introduction of pneumococcal conjugate vaccine. Pediatrics. 2014 Dec;134(6):e1528-1536.
37. Phuong LK, Cheung A, Templeton T, Abebe T, Ademi Z, Buttery J, et al. Epidemiology of childhood invasive pneumococcal disease in Australia: a prospective cohort study. Arch Dis Child. 2024 Dec 13;110(1):52–8.
38. Grewal R, Hillier K, Deeks SL, Yeung AH, Wilson SE, Wijayasri S, et al. Invasive Pneumococcal Disease Epidemiology and Serotype Replacement After the Introduction of the 13-Valent Pneumococcal Conjugate Vaccine in Ontario, Canada, 2007-2022. Open Forum Infect Dis. 2024 June;11(6):ofae275.
39. Szczepionka przeciw pneumokokom [Internet]. Szczepienia.Info. [cited 2025 Dec 12]. Available from: https://szczepienia.pzh.gov.pl/szczepionki/pneumokoki/
40. Pan LL, Gao Z, Zhou WW, Li MJ, Fang WJ, Ji WJ, et al. Safety of the 15-valent pneumococcal conjugate vaccine: A phase I clinical trial. Hum Vaccines Immunother. 2022 Nov 30;18(6):2116881.
41. Korbal P, Wysocki J, Jackowska T, Kline M, Tamimi N, Drozd J, et al. Phase 3 Safety and Immunogenicity Study of a Three-dose Series of Twenty-valent Pneumococcal Conjugate Vaccine in Healthy Infants and Toddlers. Pediatr Infect Dis J. 2024 June 1;43(6):587–95.
42. Szczepienie przeciwko pneumokokom – podstawy prawne i zasady realizacji u dzieci i młodzieży [Internet]. 2018 [cited 2025 Dec 12]. Available from: https://forumpediatrii.pl/artykul/forumpediatrii.pl/artykul/szczepienie-przeciwko-pneumokokom-podstawy-prawne-i-zasady-realizacji-u-dzieci-i-mlodziezy
43. Schjørring CB, Lomholt FK, Valentiner-Branth P, Dalby T, Fuursted K, Slotved HC, et al. Increasing incidence of serotype 38 invasive pneumococcal disease driven by the ST393 clone among children, Denmark 2022-2024. Sci Rep. 2025 May 2;15(1):15446.
44. Tereziu S, Minter DA. Pneumococcal Vaccine. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2025 [cited 2025 Dec 12]. Available from: http://www.ncbi.nlm.nih.gov/books/NBK507794/
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2026 Kinga Woźniak, Sandra Dachowska, Aleksandra Fałczyńska, Jan Haraj, Maria Namysł, Simon Matczak, Maciej Bieniek, Marcin Sobkowiak
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
The periodical offers access to content in the Open Access system under the Creative Commons Attribution-NonCommercial-ShareAlike 4.0
Stats
Number of views and downloads: 11
Number of citations: 0
